Inogen (INGN) EBITDA Margin (2013 - 2026)
Inogen's (INGN) quarterly EBITDA Margin came in at 10.97% in Q1 2026, down 166.0% year-on-year from 16.62% in Q1 2025, and up 3.67% on a QoQ basis from 11.39% in Q4 2025.
Inogen (INGN) EBITDA Margin (2013 - 2026) Analysis & Trends
Inogen (INGN) has 14 years of EBITDA Margin data on file, last reported at 10.97% in Q1 2026.
- On a quarterly basis, EBITDA Margin fell 166.0% year-over-year to 10.97% in Q1 2026; TTM through Mar 2026 was 9.07%, a 90.0% increase from a year earlier, with the FY2025 full-year figure at 8.66%, up 400.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 10.97%, up from 11.39% in the prior quarter.
- Over the last five years, EBITDA Margin for INGN reached as high as 2.78% in Q2 2022 and fell as low as 66.4% in Q4 2022.
- Historically, EBITDA Margin has averaged 19.52% across 5 years, with a median of 11.39% in 2025.
- Across the five-year window, EBITDA Margin slumped 6031 bps in 2022 and jumped 4687 bps in 2024, its largest moves.
- Year by year, EBITDA Margin stood at 66.4% in 2022, then surged by 42 bps to 38.19% in 2023, then soared by 63 bps to 14.22% in 2024, then rose by 20 bps to 11.39% in 2025, then gained by 4 bps to 10.97% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 10.97% in Q1 2026, 11.39% in Q4 2025, and 7.7% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Inogen | 172.68 Mn | 62.51 Mn | 37.86 Mn | -10.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.97% |
| Dec 31, 2025 | -11.39% |
| Sep 30, 2025 | -7.70% |
| Jun 30, 2025 | -6.64% |
| Mar 31, 2025 | -9.30% |
| Dec 31, 2024 | -14.22% |
| Sep 30, 2024 | -8.77% |
| Jun 30, 2024 | -7.96% |
| Mar 31, 2024 | -20.86% |
| Dec 31, 2023 | -38.19% |
| Sep 30, 2023 | -55.64% |
| Jun 30, 2023 | -14.07% |
| Mar 31, 2023 | -30.37% |
| Dec 31, 2022 | -66.40% |
| Sep 30, 2022 | -9.77% |
| Jun 30, 2022 | -2.78% |
| Mar 31, 2022 | -16.90% |
| Dec 31, 2021 | -6.09% |
| Sep 30, 2021 | 7.87% |
| Jun 30, 2021 | 11.49% |